Loading clinical trials...

UNKNOWNPHASE2

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

A Study Evaluated Efficacy and Safety of CD19/22 Chimeric Antigen Receptor T Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT04539444•The First Affiliated Hospital of Soochow University

View on ClinicalTrials.gov

Summary

This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19/22 CART cells combined with PD-1 Inhibitor in relapsed/refractory B Cell Lymphoma.

Detailed Description

Though response rates have greatly improved with the development of Chimeric antigen receptor T cells (CART) therapy in refractory/relapsed B cell non-Hodgkin's lymphoma (R/R B-NHL), the response can't usually last long and relapse occurs in a large proportion of patients who receive CART cells infusion. The main reasons of relapse might be tumor antigen loss and a lack of CART cell persistence. Currently, preclinical studies have shown that there is a synergistic effect between CAR-T cell therapy and anti-PD1 pathway, and it did have efficacy in clinic. In parallel, the combined use of CART-19 and CART-22 cells has a better potential to reduce antigen escape and increase anti-tumor activity. Therefore, the combination of CD19/22 CART and PD-1 inhibitor is one of the ways to improve the therapeutic effect of CART cells. This study was conducted to explore the efficacy and safety of CD19/22 CART cells in R/R B-NHL.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. R/R B-NHL with measurable (≧1.5cm) lesions confirmed by pathological immunohistochemistry or flow cytometry ( meeting any of the following conditions):
•A.The lesion shrinkage \<50% or disease progression after 4 courses of standard first-line treatment or 2 courses of two-line treatment (primary refractory disease) B. Progress disease as the best response after hematopoietic stem cell transplantation C.Progress disease or stable disease as the best response to most recent therapy regimen
•2. Age ≥ 18 years
•3. The Eastern Cooperative Oncoloy Group (ECOG) physical condition score ≤ 2 points
•4. The main organ functions need to meet the following conditions:
•A.Left ventricular ejection fraction ≥50% B.Creatinine ≤132umol/l or creatinine clearance ≥60 ml/min C.ALT and AST≤2 upper limitation of normal D.SpO2 \> 90%
•5. Results of pregnant test should be negative, and agree to conception control during treatment and 1 year after CAR-T infusion
•6. Expected survival exceeds 3 months
•7. Written informed consent could be acquired

Exclusion Criteria

•1. Immunosuppressant medications or steroids was used within 2 weeks before cell collection, or need to use steroids or immunosuppressant medications more than two years
•2. Uncontrolled bacteria, fungi, viruses, mycoplasma or other types of infection
•3. Active hepatitis B or hepatitis C infection
•4. HIV infection
•5. Severe acute or chronic graft-versus-host disease (GVHD)
•6. Participated in any other drug research clinical trials within 30 days before enrollment
•7. Prior CART cells therapy within 3 months before enrollment
•8. Prior allogeneic hematopoietic stem cell transplantation within 6 months before enrollment
•9. Have contraindications to the PD-1 inhibitors
•10. Uncontrolled other tumor
+2 more criteria

Locations (1)

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Key Dates

Start Date

August 1, 2020

Primary Completion Date

February 1, 2022

Completion Date

February 1, 2023

Last Updated

August 2, 2021

Enrollment

ESTIMATED participants

Conditions

Relapsed Non Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma

Interventions

CD19/22 CART

BIOLOGICAL

Tislelizumab

DRUG

Contacts

Caixia Li, M.D.

CONTACT

+86 512 67781856 licaixia@suda.edu.cn

Jia Chen, M.D.

CONTACT

+86 512 67781856 chenjiasuzhou@gmail.com

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT06026319

Non-hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma+8 more

View study

RECRUITINGPHASE1/PHASE2

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119

Colorectal CarcinomaEndometrial Carcinoma+20 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 2, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Inclusion Criteria

Exclusion Criteria

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies